1-5 of 5
Fu-Tien Liao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract IA21: Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer

Jamunarani Veeraraghavan, Fu-Tien Liao, Lanfang Qin, Tia Gordon, Alekya Raghavan, Caroline Sabotta, Rachel Kaplan, Carolina Gutierrez, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): IA21.
https://doi.org/10.1158/1538-7445.ADVBC23-IA21
Published: 01 February 2024
View article titled, Abstract IA21: Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer
Journal Articles

Abstract 386: Metastatic models of resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC)

Fu-Tien Liao, Lanfang Qin, Martin J. Shea, Igor Bado, Yi-Hsuan Wu, Ling Wu, Yang Gao, Sarmistha Nanda, Tia Gordon, Chia Chia Liu, Xiang H.-F. Zhang, C. Kent Osborne, Mothaffar F. Rimawi, Jamunarani Veeraraghavan, Rachel Schiff
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 386.
https://doi.org/10.1158/1538-7445.AM2023-386
Published: 04 April 2023
View article titled, Abstract 386: Metastatic models of resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC)
Journal Articles

Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models

Fu-Tien Liao, Tia Gordon, Chia Chia Liu, Pier Selenica, Yingjie Zhu, Juber Patel, Sarmistha Nanda, Lanfang Qin, Xiaoyong Fu, Andrea Gazzo, Antonio Marra, Juan Blanco-Heredia, Britta Weigelt, Jorge Reis-Filho, C. Kent Osborne, Mothaffar Rimawi, Rachel Schiff, Jamunarani Veeraraghavan
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P1-13-17.
https://doi.org/10.1158/1538-7445.SABCS22-P1-13-17
Published: 01 March 2023
View article titled, Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models
Journal Articles

Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications

Jamunarani Veeraraghavan, Fu-Tien Liao, Tia Gordon, Pier Selenica, Sarmistha Nanda, Lanfang Qin, Yingjie Zhu, Juber A. Patel, Andrea Gazzo, Fabio Stossi, Michael A. Mancini, Carolina Gutierrez, Britta Weigelt, Jorge S. Reis-Filho, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB517A.
https://doi.org/10.1158/1538-7445.AM2022-LB517A
Published: 15 June 2022
View article titled, Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications
Journal Articles

Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen–Induced Lung Cancer and Determines the Efficacy of Immunotherapy

Chia-Hsin Liu, Zhong Chen, Kong Chen, Fu-Tien Liao, Chia-En Chung, Xiaoping Liu, Yu-Chun Lin, Phouthone Keohavong, George D. Leikauf, Yuanpu Peter Di
Journal: Cancer Research
Cancer Res (2021) 81 (1): 144–157.
https://doi.org/10.1158/0008-5472.CAN-20-1994
Published: 04 January 2021
View article titled, Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen–Induced Lung Cancer and Determines the Efficacy of Immunotherapy
Open the PDF for Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen–Induced Lung Cancer and Determines the Efficacy of Immunotherapy in another window
Includes: Supplementary data